Alto Neuroscience (ANRO) Stock Price, News & Analysis

Company Overview

Alto Neuroscience is a clinical‐stage biotechnology company focused on advancing precision medicine for psychiatric and neurobehavioral disorders. Founded in 2017, Alto combines advanced biomarker discovery, computational modeling and translational neuroscience to address the high unmet need in conditions such as major depressive disorder and schizophrenia. By stratifying patients based on neurobiological profiles rather than conventional symptom checklists, the company aims to improve response rates and reduce time to effective treatment.

The company’s proprietary platform integrates electroencephalography (EEG), cognitive performance measures and genetic data to identify distinct patient subtypes. Alto applies these insights to both its internal pipeline and collaborative programs, working on novel small molecules and reformulations of existing compounds. Lead programs are designed to target cognitive impairment, anhedonia and other core features of mood and psychotic disorders, with the goal of advancing precision therapies through Phase II clinical trials.

Headquartered in New York City and with a research hub in Cambridge, Massachusetts, Alto Neuroscience operates across North America and Europe. The company has formed strategic partnerships with academic research centers, patient advocacy groups and clinical consortia to validate its biomarker signatures and accelerate patient recruitment. These collaborations enable Alto to leverage real‐world data and broaden access to specialized diagnostic assessments.

Alto’s leadership team is composed of seasoned neuroscientists, clinicians and industry executives. David Di Lorenzo, MD, serves as Chief Executive Officer, bringing deep expertise in psychiatric drug development and translational research. Supported by a board of directors with backgrounds in biotechnology investment and neuropharmacology, Alto is positioned to transform the treatment landscape for neuropsychiatric conditions through data‐driven precision medicine.

Key Stats

• Today's Range: $2.50 to $2.66
• 50-Day Range: $2.17 to $3.05
• 52-Week Range: $1.60 to $17.55
• Volume: 68,295 shs
• Average Volume: 410,973 shs
• Market Capitalization: $70.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Moderate Buy

Alto Neuroscience Stock Analysis - MarketRank™

Alto Neuroscience scored higher than 38% of companies evaluated by MarketBeat, and ranked 733rd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alto Neuroscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Alto Neuroscience has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alto Neuroscience are expected to grow in the coming year, from ($2.54) to ($2.39) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alto Neuroscience is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alto Neuroscience is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alto Neuroscience has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.35% of the float of Alto Neuroscience has been sold short.

Short Interest Ratio / Days to Cover

Alto Neuroscience has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in Alto Neuroscience has recently decreased by 27.96%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alto Neuroscience does not currently pay a dividend.

Dividend Growth

Alto Neuroscience does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.35% of the float of Alto Neuroscience has been sold short.

Short Interest Ratio / Days to Cover

Alto Neuroscience has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in Alto Neuroscience has recently decreased by 27.96%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 5 people have searched for ANRO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alto Neuroscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.13% of the stock of Alto Neuroscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

ANRO Stock Analysis - Frequently Asked Questions

How have ANRO shares performed this year?

Alto Neuroscience's stock was trading at $4.23 at the start of the year. Since then, ANRO shares have decreased by 38.4% and is now trading at $2.6050.

How were Alto Neuroscience's earnings last quarter?

Alto Neuroscience, Inc. (NYSE:ANRO) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.06.

When did Alto Neuroscience IPO?

Alto Neuroscience (ANRO) raised $129 million in an IPO on Friday, February 2nd 2024. The company issued 8,040,000 shares at a price of $16.00 per share.

How do I buy shares of Alto Neuroscience?

Shares of ANRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Alto Neuroscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alto Neuroscience investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:ANRO
• Previous Symbol: NYSE:ANRO
• CIK: 1999480
• Web: www.altoneuroscience.com
• Phone: (650) 200-0412
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Alto Neuroscience: $8.50
• High Price Target: $10.00
• Low Price Target: $4.00
• Potential Upside/Downside: +226.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$61.43 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -39.35%
• Return on Assets: -33.86%

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 22.53
• Quick Ratio: 22.53

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.62 per share
• Price / Book: 0.46

Miscellaneous

• Outstanding Shares: 27,072,000
• Free Float: 24,059,000
• Market Cap: $70.52 million
• Optionable: N/A
• Beta: 1.65